Form 4 for UTHR UNITED THERAPEUTICS Corp
Accepted 2026-04-28 17:30:27 ET · period of report 2026-04-27 · accession 0001636178-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-28 17:30 | 2026-04-27 | UTHR | EDGEMOND JAMES | CFO AND Treas | M - OptEx | $135.42 | +10.0K | 28.9K | +53% | +$1.35M |
| DMT | 2026-04-28 17:30 | 2026-04-27 | UTHR | EDGEMOND JAMES | CFO AND Treas | S - Sale+OE | $568.83 | -10.0K | 18.9K | -35% | -$5.69M |
| DT | 2026-04-28 17:30 | 2026-04-27 | UTHR | EDGEMOND JAMES | CFO AND Treas | M - OptEx | $0.00 | -10.0K | 52.5K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-27 | M | A | 10,000 | $135.42 | 28,876 | D | — | — | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
| 2 | Common | Common Stock | 2026-04-27 | S | D | 1,716 | $565.85 | 27,160 | D | — | — | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $565.22 to $566.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-04-27 | S | D | 1,449 | $566.73 | 25,711 | D | — | — | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $566.36 to $567.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-04-27 | S | D | 919 | $567.81 | 24,792 | D | — | — | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. (F4) This transaction was executed in multiple trades at prices ranging from $567.41 to $568.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2026-04-27 | S | D | 1,107 | $569.01 | 23,685 | D | — | — | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. (F5) This transaction was executed in multiple trades at prices ranging from $568.55 to $569.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2026-04-27 | S | D | 2,405 | $570.05 | 21,280 | D | — | — | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. (F6) This transaction was executed in multiple trades at prices ranging from $569.59 to $570.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Common | Common Stock | 2026-04-27 | S | D | 1,755 | $571.10 | 19,525 | D | — | — | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. (F7) This transaction was executed in multiple trades at prices ranging from $570.62 to $571.605. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 8 | Common | Common Stock | 2026-04-27 | S | D | 649 | $571.92 | 18,876 | D | — | — | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. (F8) This transaction was executed in multiple trades at prices ranging from $571.62 to $572.415. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 9 | Derivative | Stock Option | 2026-04-27 | M | D | 10,000 | $0.00 | 52,500 | D | $135.42 · 2023-03-15 to 2027-03-15 | 10,000 Common Stock | (F1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |